Kenvue CEO Discusses Growth Outlook After J&J Unit Jumps 20% in Market Debut
Johnson & Johnson's consumer-health unit Kenvue made its debut on the New York Stock Exchange and jumped about 20% on Thursday. Thibaut Mongon, CEO of Kenvue, joined Cheddar News to discuss business growth goals and what lies ahead for its well-known pipeline of products, including Band-Aid, Neutrogena, Tylenol, among others.
As the DOJ potentially prepares to file criminal charges against Boeing, an industry expert breaks down what went wrong – and how it could make things right.
The Fed chair seems pleased with how far inflation has fallen, but according to this analyst, we could be waiting until 2025 to hit that crucial 2% goal.
While the Fed has made it clear that it won’t consider cutting rates until at least September, one analyst is expecting a whopping seven cuts in a row.
The NASDAQ’s Executive Vice President of Corporate Platforms breaks down why you’ll probably see a lot of companies going public in September and December.